Product description: Alvesco® (ciclesonide), developed and marketed in collaboration with Sunovion (formerly Sepracor), is an inhaled corticosteroid for the treatment of asthma. This prescription product has a unique mechanism of action that combines proven efficacy with good tolerability. Alvesco® is currently available in more than 40 countries.
Medical need: Asthma is a chronic lung disease caused by airway inflammation and constriction. It is characterised by a variety of symptoms, including wheezing, coughing and a tightening of the airways, causing shortness of breath. In severe cases, asthma can be life-threatening. There are more than 300 million asthma sufferers around the world. The prevalence of asthma is increasing steadily, especially among children.
Not all products or indications are available in all countries. Regulatory requirements in various countries limit the product information that we can provide. Please consult your physician about any medical condition or prescription product.